WuXi Biologics (2269.HK), a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced yesterday its strategic collaboration with Brii Biosciences, a biotechnology company that operates in China and the US, focusing on accelerating innovation and optimising access to serve the need of Chinese patients and public health.

The collaboration is aimed at discovering and developing bispecific antibodies to treat infectious diseases and other immunologic disorders. It is intended to further integrate the advantages of both firms and to accelerate the development of Brii Bio's pipeline. According to the terms of the contract, Brii Bio has access to WuXi Biologics' entire antibody platform capabilities including the WuXiBody technology to discover novel bispecific antibodies. WuXi Biologics will also be the exclusive development and manufacturing partner of any novel bispecific antibodies discovered from the WuXiBody Platform.

Dr Zhi Hong, co-founder and chief executive officer of Brii Biosciences, said, 'Discovery of novel immunotherapeutics modulating the host immune responses represents an untapped paradigm that may improve the treatment of infectious diseases. WuXi Biologics has successfully grown and expanded its capability and capacity in biopharmaceutical, which will enable us to translate target insight to key therapeutic modalities and innovate in China for the world.'